| Oct 31 |
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
|
| Oct 10 |
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
|
| Oct 9 |
Lipocine signs supply and distribution agreement with Pharmalink for Tlando
|
| Oct 8 |
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
|
| Oct 2 |
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
|
| Sep 30 |
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference
|
| Sep 5 |
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
|
| Aug 27 |
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 8 |
Lipocine GAAP EPS of -$0.56 beats by $0.22, revenue of $0.09M misses by $0.2M
|
| Aug 8 |
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024
|
